07/13/2021
Labs in Europe that perform standard COVID-19 testing can now test for SARS-CoV-2, influenza A, and influenza B simultaneously during the flu season, using the Reliance SARS-CoV-2/FluA/FluB™ RT-PCR Kit (IVD).
06/23/2021
The solution includes chromogenic medium and a selective supplement that can detect these bacteria without the need for a confirmation step, delivering results in less than 24 hours.
06/06/2021
The StarBright Violet 570, StarBright Violet 670, and StarBright Violet 710 Dyes offer improved brightness and resolution.
05/11/2021
The kit improves assay efficiency by eliminating irrelevant RNA fragments from an RNA-Seq library.
04/29/2021
The real-time reverse-transcription PCR (RT-PCR) assay kit can detect nucleic acid in SARS-CoV-2, the virus associated with COVID-19 disease.
04/19/2021
The assays detect current SARS-CoV-2 variants of concern including P.1, B.1.351, and B.1.1.7 by distinguishing specific mutations using reverse transcription PCR (RT-PCR)
04/01/2021
Bio-Rad has announced the launch of two ddPCR Assays for Droplet Digital PCR (ddPCR) platforms that support the development and manufacture of safe and effective cell and gene therapies.
02/24/2021
The qualitative multiplex immunoassay panel provides precise, specific, and sensitive detection of IgG antibodies against four SARS-CoV-2 antigens.
02/12/2021
Bio-Rad announced that its Reliance SARS-CoV-2/FluA/FluB RT-PCR and Reliance SARS-CoV-2 RT-PCR Assay Kits were granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA).
02/08/2021
Studies address how ddPCR technology is helping to alleviate an array of pain points in cell and gene therapy QC in the areas of product safety testing, QC scale-up, and contamination detection.
